SHE:002294

5 stories mentioning SHE:002294

Every FINWIRES story that references SHE:002294, newest first.

Salubris Pharmaceuticals Unit Presents JK06's Clinical Trial Results At American Oncology Convention

Shenzhen Salubris Pharmaceuticals' (SHE:002294) unit, Salubris Biotherapeutics, presented the results of its clinical trial on the drug JK06 at the American Society of Clinical Oncology Annual Meeting, according to a Shenzhen bourse filing on Wednesday.The trials showed that the drug has safety and efficacy in patients with tumors, including non-small cell lung cancer and breast cancer.The trial enrolled 173 patients in Europe.Shares of the pharmaceutical company were down 2% at the close.

SHE:002294

Asia24d ago

Salubris Pharma's Clinical Trial Application for Lipid-Lowering Drug Accepted in China

Shenzhen Salubris Pharmaceuticals (SHE:002294) said China's drug regulator accepted its clinical trial application for SAL0195.The drug targets lipid-related diseases, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 2% in recent trade.

SHE:002294

Asia28d ago

Salubris Subsidiary Gets China Nod for Osteoporosis Injection

China's drug regulator approved Shenzhen Salubris Pharmaceuticals' (SHE:002294) subsidiary Salubris (Suzhou) Pharmaceutical's drug registration for its recombinant teriparatide for injection.The drug, a subcutaneous powder injection taken once weekly, helps treat osteoporosis in post-menopausal women with a high risk of fractures, according to a Saturday filing with the Shenzhen bourse.

SHE:002294

Asia55d ago

Salubris Pharma's 2025 Profit Rises 8%, Revenue Climbs 9%; Shares Down 3%

Shenzhen Salubris Pharmaceuticals' (SHE:002294) net profit attributable to shareholders in 2025 rose 8.3% to 651.5 million yuan from 601.6 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.Earnings per share climbed 7.4% year on year to 0.58 yuan from 0.54 yuan.Operating revenue increased 8.5% to 4.35 billion yuan from 4.01 billion yuan in the prior year.The pharmaceutical company's shares fell by over 3% during the midday trade.

SHE:002294

Asia56d ago

Salubris Pharmaceuticals' Subsidiary Presents Positive Effects of JK06 At American Association for Cancer Research

Shenzhen Salubris Pharmaceuticals' (SHE:002294) subsidiary, Salubris Biotherapeutics, presented the positive effects of the JK06 at the American Association for Cancer Research, according to a Shenzhen bourse filing on Monday.The drug was tested for metastatic tumors, including non-small cell lung cancer and breast cancer, in phases 1/2 clinical trials.The drug showed good safety and efficacy in patients during the trials.The pharmaceutical company's shares dropped 4% during the afternoon trade.

SHE:002294